Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Tanvex BioPharma, Inc. (6541.TW)
George Town, KY
Tanvex BioPharma, Inc., originally known as Ruenvex Biotech, Inc., is a biopharmaceutical company founded in 2013 and based in George Town, Cayman Islands. The firm specializes in the investigation, creation, production, and sale of biosimilar medicines, with its operations spanning Taiwan and the United States. Its core mission involves developing biosimilars aimed at treating severe conditions like neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. The company's robust product portfolio includes TX01 and TX-05, both of which have successfully completed Phase III clinical trials. Additionally, TX-04 and TX-16 are currently undergoing Phase I clinical trials, while TX-52 and other potential therapies are in the pre-clinical development stage.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.69% | -2.12% | -3.33% | -20.41% | -29.37% | -28.73% | -29.50% | -50.96% | -76.48% | -89.38% | -88.80% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+1,056.3% ★ Q1'26: +166.4% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+31.1% ★ Q1'26: +29.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-352.4% Q1'26: -476.6% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-346.2% Q1'26: -301.3% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-21.7% Q1'26: -25.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+57.7% Q1'26: +61.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.55× Q1'26: -0.99× (vs Q1'25)
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
5.41M
est: 77.00M (-93.0%)
|
22.40M
est: 13.00M (+72.3%)
|
61.41M
est: 635.00M (-90.3%)
|
34.68M
est: 4.58B (-99.2%)
|
400.97M
est: 427.50M (-6.2%)
|
1.14B
1.14B – 1.14B
+166.2% YoY
|
| EBITDA |
-1.25B
est: -77.00M (-1,527.8%)
|
-1.30B
est: -13.00M (-9,937.1%)
|
-1.75B
est: -635.00M (-176.3%)
|
-1.04B
est: -4.58B (+77.3%)
|
-1.02B
est: -427.50M (-138.9%)
|
-1.14B
-1.14B – -1.14B
-166.2% YoY
|
| EBIT |
-1.50B
est: -77.00M (-1,844.1%)
|
-1.59B
est: -13.00M (-12,103.0%)
|
-2.08B
est: -635.00M (-227.4%)
|
-1.33B
est: -4.58B (+71.0%)
|
-1.39B
est: -427.50M (-224.7%)
|
-1.14B
-1.14B – -1.14B
-166.2% YoY
|
| Net Income |
-1.54B
est: -2.69B (+42.5%)
|
-1.64B
est: -1.68B (+2.1%)
|
-2.14B
est: -1.03B (-107.4%)
|
-1.38B
|
-1.50B
est: -1.51B (+1.0%)
|
-868.77M
-868.77M – -868.77M
+42.6% YoY
|
| SGA |
219.21M
est: 13.31B (-98.4%)
|
234.74M
est: 2.25B (-89.6%)
|
453.71M
est: 109.77B (-99.6%)
|
306.52M
est: 62.47B (-99.5%)
|
394.49M
est: 5.83B (-93.2%)
|
15.53B
15.53B – 15.53B
+166.2% YoY
|
| EPS |
-13.80
est: -17.30 (+20.2%)
|
-13.55
est: -10.79 (-25.5%)
|
-16.42
est: -6.64 (-147.4%)
|
-8.90
|
-6.13
est: -6.19 (+1.0%)
|
-3.55
-3.55 – -3.55
+42.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 99.7K | 0.65% |
| 2 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 60.3K | 0.39% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Allen Y. Chao | Founder & Honorary Chairman | 20.0K | — |
| Angela Luan | Chief Financial Officer & Corporate Governance Officer | — | female |
| James Williamson | Chief Accounting Officer | — | male |
| John R. Mosack | Chief Operating Officer of US | — | male |
| Linda Grillo | Director of Sales & Marketing | — | — |
| Marc Goemans | Chief Commercial Officer | — | male |
| Miguel Carrion | Vice President of R&D - USA | — | male |
| Stephen Lam | Chief Executive Officer & Director | — | male |
| Val Chen | Vice President of Finance, Director of Operations. Management & Corporate Governance Officer | — | — |
| Zheng Xia | Chief Technology Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6541.TW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
